J&J Q2 results
This article was originally published in The Gray Sheet
Executive Summary
Ethicon sales rose 8.2% to $1.13 billion in the second quarter, driven by sutures, biosurgicals and Mentor aesthetic devices, Johnson & Johnson reported July 20. The acquisition of Acclarent also contributed to growth, the firm noted. J&J bought the Balloon Sinuplasty developer for $785 million in December (1"The Gray Sheet" Dec. 21, 2009). Advanced sterilization and Harmonic ultrasonic devices helped grow Ethicon Endo-Surgery revenues 6.6% to $1.2 billion. The Cordis division continued to struggle, with sales dropping 2.8% to $655 million. Medical devices and diagnostics sales of $6.1 billion were up 3.5% overall
You may also be interested in...
Ethicon Opens Up To Chronic Sinusitis Market With $785 Mil. Acclarent Buy
Johnson & Johnson/Ethicon will use its $785 million acquisition of Acclarent, developer of the Balloon Sinuplasty system for chronic sinusitis, as a platform for growth in the ear, nose and throat business
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.